Business Description
BioDlink International Co Ltd
ISIN : HK0000545266
Total Employee Number:
613Compare
Compare
Traded in other countries / regions
01875.Hong Kong IPO Date
2019-11-08Description
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.85 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.61 | |||||
Debt-to-EBITDA | -4.33 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.19 | |||||
Beneish M-Score | -3.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.8 | |||||
3-Year EBITDA Growth Rate | -15.9 | |||||
3-Year EPS without NRI Growth Rate | -18.2 | |||||
3-Year FCF Growth Rate | 49.3 | |||||
3-Year Book Growth Rate | -4.6 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.9 | |||||
9-Day RSI | 64.57 | |||||
14-Day RSI | 61.94 | |||||
3-1 Month Momentum % | -23.25 | |||||
6-1 Month Momentum % | -19.24 | |||||
12-1 Month Momentum % | 43.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.05 | |||||
Quick Ratio | 1.66 | |||||
Cash Ratio | 1.2 | |||||
Days Inventory | 121.61 | |||||
Days Sales Outstanding | 57.6 | |||||
Days Payable | 40.84 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.89 | |||||
Operating Margin % | -10.88 | |||||
Net Margin % | -13.52 | |||||
EBITDA Margin % | -11.93 | |||||
FCF Margin % | -3.64 | |||||
OCF Margin % | 2.12 | |||||
ROE % | -14.66 | |||||
ROA % | -7.21 | |||||
ROIC % | -8.55 | |||||
3-Year ROIIC % | -72.84 | |||||
ROC (Joel Greenblatt) % | -12.79 | |||||
ROCE % | -8.43 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 335 | |||||
PS Ratio | 3.55 | |||||
PB Ratio | 4.22 | |||||
Price-to-Tangible-Book | 4.37 | |||||
Price-to-Operating-Cash-Flow | 167.5 | |||||
EV-to-EBIT | -30.47 | |||||
EV-to-EBITDA | -30.47 | |||||
EV-to-Revenue | 3.63 | |||||
EV-to-FCF | -99.86 | |||||
Price-to-GF-Value | 2.73 | |||||
Earnings Yield (Greenblatt) % | -3.28 | |||||
FCF Yield % | -1.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioDlink International Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 820.236 | ||
| EPS (TTM) (HK$) | -0.155 | ||
| Beta | 0.5924 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 0.91 | ||
| Volatility % | 89.53 | ||
| 14-Day RSI | 61.94 | ||
| 14-Day ATR (HK$) | 0.205679 | ||
| 20-Day SMA (HK$) | 3.609 | ||
| 12-1 Month Momentum % | 43.46 | ||
| 52-Week Range (HK$) | 1.7 - 5.87 | ||
| Shares Outstanding (Mil) | 725.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioDlink International Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioDlink International Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-21 | 4.02 (+1.52%) | ||
| General meeting for 2025 | 2026-06-26 13:00 | 3.32 (+2.15%) | ||
| Annual report for 2025 | 2026-04-28 | 4.51 (-2.17%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-18 | 4.33 (+2.85%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 2.49 (-3.11%) | ||
| General meeting for 2024 | 2025-06-20 10:00 | 1.95 (-0.51%) | ||
| Annual report for 2024 | 2025-04-28 | 2.03 (-0.98%) | ||
| Fourth quarter earnings results for 2024 | 2025-03-11 | 2.06 (+0.49%) |
Show
Entries
BioDlink International Co Ltd Frequently Asked Questions
What is BioDlink International Co Ltd(HKSE:01875)'s stock price today?
The current price of HKSE:01875 is HK$4.02. The 52 week high of HKSE:01875 is HK$5.87 and 52 week low is HK$1.70.
When is next earnings date of BioDlink International Co Ltd(HKSE:01875)?
The next earnings date of BioDlink International Co Ltd(HKSE:01875) is 2027-03-18 Est..
Does BioDlink International Co Ltd(HKSE:01875) pay dividends? If so, how much?
BioDlink International Co Ltd(HKSE:01875) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on BioDlink International Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers